These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9853192)

  • 21. [Beta blockers in the treatment of angina pectoris].
    Hadzi Pesić Lj
    Srp Arh Celok Lek; 1992 Jun; 120 Suppl 4():35-8. PubMed ID: 18193808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Calcium channel blockers in the treatment of cardiovascular disease].
    Halawa B
    Pol Merkur Lekarski; 2001 Jul; 11(61):83-7. PubMed ID: 11579840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
    Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
    J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Resting heart rate and cardiovascular disease].
    Brito Díaz B; Alemán Sánchez JJ; Cabrera de León A
    Med Clin (Barc); 2014 Jul; 143(1):34-8. PubMed ID: 23937816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of beta-blockers in chronic congestive heart failure.
    Mahanonda N; Samranthin M; Panyarachun S
    J Med Assoc Thai; 2000 Oct; 83(10):1240-7. PubMed ID: 11143491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
    Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure.
    Bunch TJ; Muhlestein JB; Bair TL; Renlund DG; Lappé DL; Jensen KR; Horne BD; Carter MA; Anderson JL;
    Am J Cardiol; 2005 Apr; 95(7):827-31. PubMed ID: 15781009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of beta-blockers in the treatment of stable angina pectoris.
    de Muinck ED; Lie KI
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S123-8. PubMed ID: 11527115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes?
    Pourdjabbar A; Lapointe N; Rouleau JL
    Can J Cardiol; 2002 May; 18 Suppl A():7A-14A. PubMed ID: 12045788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Heart rate as a therapeutic target for stable angina. Role of anti-ischemic agents and their underuse in Italy].
    Casella G; Di Pasquale G; Tavazzi L; Maggioni AP
    G Ital Cardiol (Rome); 2007 Apr; 8(4):207-14. PubMed ID: 17506292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacology of calcium antagonists].
    Klaus W
    Fortschr Med; 1984 Jul; 102(27-28):728-31. PubMed ID: 6479816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers.
    Flannery G; Gehrig-Mills R; Billah B; Krum H
    Am J Cardiol; 2008 Mar; 101(6):865-9. PubMed ID: 18328855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC
    Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality.
    Habib G
    Clin Ther; 1997; 19 Suppl A():39-52. PubMed ID: 9385504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcium entry blockers and cardiovacular failure.
    Vanhoutte PM
    Fed Proc; 1981 Dec; 40(14):2882-87. PubMed ID: 7308499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The present status and prospects of therapeutic use of beta-blockers in diseases of the cardiovascular system].
    Kuzelová M; Svec P
    Ceska Slov Farm; 1998 Feb; 47(1):4-9. PubMed ID: 9600149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic problems in hyperkinetic heart syndrome].
    Rameis H; Magometschnigg D
    Acta Med Austriaca; 1984; 11(1):17-22. PubMed ID: 6143464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Do calcium antagonists protect the heart?].
    Refsum H
    Tidsskr Nor Laegeforen; 1990 Feb; 110(5):618-21. PubMed ID: 2309216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.